17 studies were found.

1.		Recruiting	Adjuvant Hypofractionated Intensity-Modulated Radiation Therapy With Incorporated Boost in Treating Patients With Early-Stage Breast Cancer Conditions: stage I breast cancer; stage II breast cancer; breast cancer in situ
2.		Recruiting	Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer Conditions: adenocarcinoma of the pancreas; recurrent pancreatic cancer; stage IVA pancreatic cancer; stage IVB pancreatic cancer
3.		Recruiting	Bone Marrow Transplantation Plus Cyclophosphamide and Total-Body Irradiation in Treating Patients With Hematologic Cancer Conditions: Acute Lymphocytic Leukemia; Acute Myeloid Leukemia; atypical chronic myeloid leukemia; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia; ...
4.		Recruiting	Bortezomib as First-Line Systemic Therapy in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder Conditions: adult primary liver cancer; extrahepatic bile duct cancer; Gallbladder Cancer
5.		Recruiting	Celecoxib and Rosiglitazone in Treating Patients Who Are Undergoing Cystoscopic Surveillance for Early-Stage Noninvasive Carcinoma of the Bladder or Radical Cystectomy for Muscle-Invasive Carcinoma of the Bladder Conditions: stage 0 bladder cancer; stage I bladder cancer; stage II bladder cancer; stage III bladder cancer; stage IV bladder cancer; ...
6.		Recruiting	Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Condition: Non-small cell lung cancer
7.		Recruiting	Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer Conditions: stage II non-small cell lung cancer; stage IIIA non-small cell lung cancer; stage IIIB non-small cell lung cancer
8.		Recruiting	Comparison of Two Radiation Therapy Regimens in Treating Patients With Stage II or Stage III Prostate Cancer Conditions: stage II prostate cancer; stage III prostate cancer; adenocarcinoma of the prostate
9.		Recruiting	Computed Tomography (CT) Scans Using CT-On-Rails™ to Pinpoint the Location of the Tumor in Treating Patients With Prostate Cancer Conditions: recurrent prostate cancer; stage I prostate cancer; stage II prostate cancer; stage III prostate cancer; stage IV prostate cancer
10.		Recruiting	Genetic and Environmental Risk Assessment for Colorectal Cancer in Healthy Participants Conditions: Colon Cancer; Rectal Cancer
11.		Recruiting	High-Dose Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Amyloidosis Conditions: refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; primary systemic amyloidosis
12.		Recruiting	Intensity-Modulated Radiation Therapy With Incorporated Boost and Capecitabine Before Surgery in Treating Patients With Locally Advanced Rectal Cancer Conditions: stage II rectal cancer; stage III rectal cancer; adenocarcinoma of the rectum
13.		Recruiting	Intensity-Modulated Radiation Therapy With or Without Decreased Radiation Dose to Erectile Tissue in Treating Patients With Stage II Prostate Cancer Conditions: sexual dysfunction and infertility; sexuality and reproductive issues; adenocarcinoma of the prostate; stage II prostate cancer
14.		Recruiting	Neoadjuvant Chemoradiotherapy Followed By Surgery in Treating Patients With Limited-Stage Small Cell Lung Cancer Condition: limited stage small cell lung cancer
15.		Recruiting	Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer Conditions: stage IV prostate cancer; adenocarcinoma of the prostate
16.		Recruiting	Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer Conditions: Stage IV Renal Cell Cancer; recurrent renal cell cancer; renal clear cell carcinoma
17.		Recruiting	Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/neu-Expressing Cancer Condition: unspecified adult solid tumor, protocol specific